No products in the cart.
Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-725
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Chronic hepatitis C (CHC) is one of the most common causes of chronic liver disease. Albinterferon alfa-2b (alb-IFN) is an 85.7-kilodalton protein consisting of recombinant human interferon (IFN) alfa-2b genetically fused to recombinant human albumin. alb-IFN retains the antiviral properties of IFN alfa, with significant suppression of HCV RNA in the replicon system.
| Products Name (INN Index) | Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR |
|---|---|
| INN Name | albinterferon alfa- 2b |
| Target | IFNAR1 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – ALB (albumin, human serum albumin, HSA) 25-609 – IFNA2 (interferon alpha 2) *b (R46,H57) 24-188 |
| VD LC | Fusion – ALB (albumin, human serum albumin, HSA) 25-609 – IFNA2 (interferon alpha 2) *b (R46,H57) 24-188 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Human?Genome Sciences?Inc. (HGSI) (Rockville MD USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNAR1 |
| Package |
Previous slide
Next slide
